nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

23.02.2019 | Review – Clinical Oncology

T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances

verfasst von: Lin Yu, Jianhua Wang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Globally, cancer is a critical illness which seriously threatens human health. T-cell-based cancer immunotherapy for some patients has demonstrated impressive achievements including chimeric antigen receptor T cells, immune checkpoint inhibitors and T cell-redirecting bispecific antibodies (TRBAs). TRBAs recruit T cells to lyse cancer cells bypassing the antigen presentation through the major histocompatibility complex pathways. In this review we summarized the TRBAs formats, biophysical characteristics, the preclinical and clinical trial results, as well as the challenges faced by TRBAs in tumour therapy.

Methods

Herein the relevant literature and clinical trials from the PubMed and ClinicalTrials.gov database.

Results

The advances in protein engineering technology have generated diverse TRBAs format which can be classified into two categories: IgG-like TRBAs and non-IgG-like TRBAs. Multiple applications of TRBAs showed encouraging curative effect and entered clinical trials for lymphoid malignancy and solid tumour.

Conclusions

TRBA is a powerful tool for the cancer treatment and the clinical studies showed potent anti-tumour efficacy in hematologic malignancies. Although the clinical outcomes of TRBAs in solid tumours are less satisfied than hematologic malignancies, many preclinical antibodies and combination therapies are being evaluated

Aigner M et al (2013) T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 27:1107–1115. https://doi.org/10.1038/leu.2012.341 CrossRefPubMed

Al-Hussaini M et al (2016) Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity. retargeting platform. Blood 127:122–131. https://doi.org/10.1182/blood-2014-05-575704 CrossRefPubMedPubMedCentral

Bacac M et al (2016) A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the Treatment of solid tumors. Clin Cancer Res 22:3286–3297. https://doi.org/10.1158/1078-0432.CCR-15-1696 CrossRefPubMed

Banchereau J, Palucka K (2018) Immunotherapy: cancer vaccines on the move. Nat Rev Clin Oncol 15:9–10. https://doi.org/10.1038/nrclinonc.2017.149 CrossRefPubMed

Bannerji R et al (2016) Phase 1 study of REGN1979, an anti-CD20 × anti-CD3 bispecific monoclonal antibody, in patients with CD20 + B-cell malignancies previously treated with CD20-directed antibody therapy. Blood 128:621–621

Barlev A, Lin VW, Katz A, Hu K, Cong Z, Barber B (2017) Estimating long-term survival of adults with philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia treated with blinatumomab using historical data. Adv Ther 34:148–155. https://doi.org/10.1007/s12325-016-0447-x CrossRefPubMed

Beatty GL, Gladney WL (2015) Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 21:687–692. https://doi.org/10.1158/1078-0432.CCR-14-1860 CrossRefPubMed

Blankenship JW et al (2016) Abstract 4995: anti-ROR1 x anti-CD3 ADAPTIR™ molecule, ES425, redirects T-cell cytotoxicity and inhibits tumor growth in preclinical models of triple-negative breast cancer. Can Res 76:4995–4995. https://doi.org/10.1158/1538-7445.am2016-4995 CrossRef

Bossi G, Buisson S, Oates J, Jakobsen BK, Hassan NJ (2014) ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. Cancer Immunol Immunother CII 63:437–448. https://doi.org/10.1007/s00262-014-1525-z CrossRefPubMed

Buhmann R, Michael S, Juergen H, Horst L, Peschel C, Kolb HJ (2013) Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial. J Transl Med. https://doi.org/10.1186/1479-5876-11-160 CrossRefPubMedPubMedCentral

Byun DJ, Wolchok JD, Rosenberg LM, Girotra M (2017) Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13:195. https://doi.org/10.1038/nrendo.2016.205 CrossRefPubMedPubMedCentral

Cameron F, Whiteside G, Perry C (2011) Ipilimumab: first global approval. Drugs 71:1093–1104. https://doi.org/10.2165/11594010-000000000-00000 CrossRefPubMed

Chelius D et al (2010) Structural and functional characterization of the trifunctional antibody catumaxomab. mAbs 2:309–319 https://doi.org/10.4161/mabs.2.3.11791 CrossRefPubMedPubMedCentral

Cheng P et al (2017) Immunodepletion of MDSC by AMV564, a novel tetravalent bispecific CD33/CD3 T cell engager restores immune homeostasis in MDS in vitro. Blood 130:51–51

Chichili GR et al (2015) A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aaa5693 CrossRefPubMed

Chu SY et al (2014a) Immunotherapy with long-lived anti-CD20 × anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human B cell lines and of circulating and lymphoid B cells in monkeys: a potential therapy for B cell lymphomas and Leukemias. Blood 124:3111–3111

Chu SY et al (2014b) Immunotherapy with long-lived anti-CD123 × anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human AML cell lines and of CD123 + cells in monkeys: a potential therapy for acute myelogenous Leukemia. Blood 124:2316–2316CrossRef

Comeau MR et al (2018) Abstract 1786: APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity, induces potent T-cell activation, proliferation and cytotoxicity with limited cytokine release. Can Res 78:1786–1786. https://doi.org/10.1158/1538-7445.am2018-1786 CrossRef

de Zafra C et al (2017) Preclinical characterization of AMG 424, a novel humanized T cell-recruiting bispecific anti-CD3/CD38. Antib Blood 130:500–500

Ellwanger K et al (2017) Highly specific and effective targeting of EGFRvIII-positive tumors with TandAb. Antibod Front Oncol 7:100. https://doi.org/10.3389/fonc.2017.00100 CrossRef

Esteban RE, Christianne B, Alvaro A, Demichelis-Gomez R (2018) Prognostic effect of CD20 expression in Adult B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 18:361–367. https://doi.org/10.1016/j.clml.2018.02.013 CrossRefPubMed

Fan G, Wang Z, Hao M, Li J (2015) Bispecific antibodies and their applications. J Hematol Oncol. https://doi.org/10.1186/s13045-015-0227-0 CrossRefPubMedPubMedCentral

Ferl GZ, Reyes A, Sun LL, Cheu M, Oldendorp A, Ramanujan S, Stefanich EG (2018) A preclinical population pharmacokinetic model for anti-CD20/CD3 T-cell-dependent bispecific antibodies. Clin Transl Sci 11:296–304 https://doi.org/10.1111/cts.12535 CrossRefPubMedPubMedCentral

Fiedler WM et al (2010) Phase I safety and pharmacology study of the EpCAM/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric, or lung cancer. J Clin Oncol 28:2573–2573. https://doi.org/10.1200/jco.2010.28.15_suppl.2573 CrossRef

Fiedler WM et al (2012) A phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors. J Clin Oncol 30:2504–2504. https://doi.org/10.1200/jco.2012.30.15_suppl.2504 CrossRef

Fisher TS et al (2018) A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice. Cancer Immunol Immunother CII 67:247–259. https://doi.org/10.1007/s00262-017-2081-0 CrossRefPubMed

Fraietta JA et al (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563–571. https://doi.org/10.1038/s41591-018-0010-1 CrossRefPubMedPubMedCentral

Friedrich M et al (2012) Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther 11:2664–2673. https://doi.org/10.1158/1535-7163.mct-12-0042 CrossRefPubMed

Gaudet F et al (2016) Development of a CD123 × CD3 bispecific antibody (JNJ-63709178) for the treatment of acute myeloid leukemia (AML). Blood 128:2824–2824CrossRef

Ghosh A, Heston WDW (2004) Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528–539. https://doi.org/10.1002/jcb.10661 CrossRefPubMed

Godwin CD, Bates OM, Laszlo GS, Gottschalk R, Comeau MR, Hoyos GH, Walter RB (2017) Bispecific anti-CD123 × anti-CD3 Adaptir™ molecules APVO436 and APVO437 have broad activity against primary human AML cells in vitro. Blood 130:2639–2639

Goebeler ME et al (2016) Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-hodgkin lymphoma: final results from a phase I study. J Clin Oncol 34:1104–1111. https://doi.org/10.1200/JCO.2014.59.1586 CrossRefPubMed

Gokbuget N, Dombret H (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131:1522–1531 https://doi.org/10.1182/blood-2017-08-798322 CrossRefPubMedPubMedCentral

Haense N et al (2016) A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BMC Cancer 16:420. https://doi.org/10.1186/s12885-016-2449-0 CrossRefPubMedPubMedCentral

Hallet J, Law CHL, Cukier M, Saskin R, Liu N, Singh S (2015) Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation and outcomes. Cancer 121:589–597. https://doi.org/10.1002/cncr.29099 CrossRefPubMed

Han TH, Guenot J, Denney WS, Feldman EJ (2018) The therapeutic potential of AMV564, a novel bispecific bivalent (2 × 2) T-cell engager, for the treatment of CD33-expressing hematologic malignancies. Can Res 78:5548–5548. https://doi.org/10.1158/1538-7445.am2018-5548 CrossRef

Hassan NJ et al (2014) Abstract 3525: IMCgp100: a novel bi-specific biologic for the treatment of malignant melanoma. Can Res 72:3525–3525. https://doi.org/10.1158/1538-7445.am2012-3525 CrossRef

Hauswirth AW et al (2007) Expression of the target receptor CD33 in CD34+/CD38−/CD123 + AML stem cells. Eur J Clin Investig 37:73–82. https://doi.org/10.1111/j.1365-2362.2007.01746.x CrossRef

Hernandez-Hoyos G et al (2016) MOR209/ES414, a novel bispecific antibody targeting PSMA for the treatment of metastatic castration-resistant prostate cancer. Mol Cancer Ther 15:2155–2165. https://doi.org/10.1158/1535-7163.MCT-15-0242 CrossRefPubMed

Herrmann I et al (2010) Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. PLoS One 5:e13474 https://doi.org/10.1371/journal.pone.0013474 CrossRefPubMedPubMedCentral

Hipp S et al (2017) A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia 31:1743–1751. https://doi.org/10.1038/leu.2016.388 CrossRefPubMed

Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S (2014) Drug resistance in cancer: an overview. Cancers 6:1769CrossRefPubMedPubMedCentral

Ishiguro T et al (2017) An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aal4291 CrossRefPubMed

Johnson S et al (2010) Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol 399:436–449. https://doi.org/10.1016/j.jmb.2010.04.001 CrossRefPubMed

Kantarjian H et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376:836–847. https://doi.org/10.1056/NEJMoa1609783 CrossRefPubMedPubMedCentral

Kebenko M et al (2018) A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE^®) antibody construct, in patients with refractory solid tumors. Oncoimmunology. https://doi.org/10.1080/2162402x.2018.1450710 CrossRefPubMedPubMedCentral

Kiewe P et al (2006) Phase I trial of the trifunctional anti-HER2 × anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 12:3085–3091. https://doi.org/10.1158/1078-0432.CCR-05-2436 CrossRefPubMed

Klausen U, Jorgensen NGD, Grauslund JH, Holmstrom MO, Andersen MH (2018) Cancer immune therapy for lymphoid malignancies: recent advances. Semin Immunopathol. https://doi.org/10.1007/s00281-018-0696-7 CrossRefPubMed

Klinger M et al (2012) Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119:6226–6233. https://doi.org/10.1182/blood-2012-01-400515 CrossRefPubMed

Knodler M et al (2018) Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. Br J Cancer. https://doi.org/10.1038/s41416-018-0150-6 CrossRefPubMedPubMedCentral

Labrijn AF et al (2011) Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3–CH3 interaction strength. J Immunol 187:3238–3246. https://doi.org/10.4049/jimmunol.1003336 CrossRefPubMed

Labrijn AF et al (2013) Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci USA 110:5145–5150. https://doi.org/10.1073/pnas.1220145110 CrossRefPubMedPubMedCentral

Lee S-H et al. (2017a) Abstract 3633: Anti-SSTR2 × anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target-dependent T cell activation in monkeys: a potential immunotherapy for neuroendocrine tumors. Cancer Res 77:3633–3633 https://doi.org/10.1158/1538-7445.am2017-3633 CrossRef

Lee S-H et al (2017b) Abstract 3633: Anti-SSTR2 × anti-CD3 bispecific antibody induces potent killing of human tumor cellsin vitroand in mice, and stimulates target-dependent T cell activation in monkeys: a potential immunotherapy for neuroendocrine tumors. Can Res 77:3633–3633. https://doi.org/10.1158/1538-7445.am2017-3633 CrossRef

Lehmann S et al (2016) In vivo fluorescence imaging of the activity of CEA TCB, a novel T-cell bispecific antibody, reveals highly specific tumor targeting and fast induction of T-cell-mediated tumor killing. Clin Cancer Res 22:4417–4427. https://doi.org/10.1158/1078-0432.CCR-15-2622 CrossRefPubMed

Liu L et al (2017) MGD011, A CD19 × CD3 dual-affinity retargeting bi-specific molecule incorporating extended circulating half-life for the treatment of B-cell malignancies. Clin Cancer Res 23:1506–1518. https://doi.org/10.1158/1078-0432.CCR-16-0666 CrossRefPubMed

Loffler A et al (2000) A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95:2098–2103PubMed

Lum LG et al (2015) Targeted T-cell therapy in stage IV breast cancer: a phase I clinical trial. Clin Cancer Res 21:2305–2314. https://doi.org/10.1158/1078-0432.CCR-14-2280 CrossRefPubMedPubMedCentral

Martinelli G et al (2017) Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome—positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol 35:1795–1802. https://doi.org/10.1200/jco.2016.69.3531 CrossRefPubMed

McAleese F, Eser M (2012) RECRUIT-TandAbs: harnessing the immune system to kill cancer cells. Fut Oncol 8:687–695. https://doi.org/10.2217/fon.12.54 CrossRef

Melero I, Rouzaut A, Motz GT, Coukos G (2014) T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov 4:522–526. https://doi.org/10.1158/2159-8290.CD-13-0985 CrossRefPubMedPubMedCentral

Middleton MR et al (2016) Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific T cell redirector with solid tumour activity: results from the FIH study in melanoma. J Clin Oncol 34:3016–3016. https://doi.org/10.1200/JCO.2016.34.15_suppl.3016 CrossRef

Moore PA et al (2011) Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 117:4542–4551. https://doi.org/10.1182/blood-2010-09-306449 CrossRefPubMed

Moore PA et al (2018) Development of MGD007, a gpA33 × CD3 bispecific DART(R) protein for T-cell immunotherapy of metastatic colorectal cancer. Mol Cancer Ther. https://doi.org/10.1158/1535-7163.MCT-17-1086 CrossRefPubMedPubMedCentral

Moretti P et al (2013) BEAT^® the bispecific challenge: a novel and efficient platform for the expression of bispecific IgGs. BMC Proc 7:O9. https://doi.org/10.1186/1753-6561-7-s6-o9 CrossRefPubMedCentral

Munoz L et al (2001) Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica 86:1261–1269PubMed

Oates J, Hassan NJ, Jakobsen BK (2015) ImmTACs for targeted cancer therapy: why, what, how, and which. Mol Immunol 67:67–74 https://doi.org/10.1016/j.molimm.2015.01.024 CrossRefPubMed

Oberst MD et al (2014) CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. mAbs 6:1571–1584 https://doi.org/10.4161/19420862.2014.975660 CrossRefPubMedPubMedCentral

Ogita Y et al (2018) A phase 1 dose escalation (DE) and cohort expansion (CE) study of ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors. J Clin Oncol 36:TPS2599–TPS2599. https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS2599 CrossRef

Oldhafer KJ, Donati M, Jenner RM, Stang A, Stavrou GA (2014) ALPPS for patients with colorectal liver metastases: effective liver hypertrophy, but early tumor recurrence. World J Surg 38:1504–1509. https://doi.org/10.1007/s00268-013-2401-2 CrossRefPubMed

Pellerin L, Chen P, Gregori S, Hernandez-Hoyos G, Bacchetta R, Roncarolo MG (2018) APVO210: a bispecific anti-CD86-IL-10 fusion protein (ADAPTIR™) to induce antigen-specific T regulatory type 1 cells. Front Immunol. https://doi.org/10.3389/fimmu.2018.00881 CrossRefPubMedPubMedCentral

Picarda E, Ohaegbulam KC, Zang X (2016) Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy. Clin Cancer Res 22:3425–3431. https://doi.org/10.1158/1078-0432.CCR-15-2428 CrossRefPubMedPubMedCentral

Pillarisetti K et al (2016) Development of a New BCMAxCD3 Duobody^® antibody for multiple myeloma. Blood 128:2116–2116

Pishvaian M et al (2016) Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen, in patients with advanced gastrointestinal adenocarcinomas. Clin Colorectal Cancer 15:345–351. https://doi.org/10.1016/j.clcc.2016.07.009 CrossRefPubMed

Poole RM (2014) Pembrolizumab: first global approval. Drugs 74:1973–1981. https://doi.org/10.1007/s40265-014-0314-5 CrossRefPubMed

Prasad V (2018) Immunotherapy: tisagenlecleucel—the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat Rev Clin Oncol 15:11–12. https://doi.org/10.1038/nrclinonc.2017.156 CrossRefPubMed

Przepiorka D et al (2015) FDA approval: blinatumomab. Clin Cancer Res 21:4035–4039. https://doi.org/10.1158/1078-0432.CCR-15-0612 CrossRefPubMed

Pulte ED et al (2018) FDA supplemental approval: blinatumomab for treatment of relapsed and refractory precursor B-cell acute lymphoblastic leukemia. Oncologist 23:1366–1371. https://doi.org/10.1634/theoncologist.2018-0179 CrossRefPubMedPubMedCentral

Reusch U et al (2015) A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. mAbs 7:584–604 https://doi.org/10.1080/19420862.2015.1029216 CrossRefPubMedPubMedCentral

Ridgway JB, Presta LG, Carter P (1997) Knobs-into-holes’ engineering of antibody CH3 domains for heavy. Protein Eng 9:617–621CrossRef

Ruella M et al (2016) Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Investig 126:3814–3826. https://doi.org/10.1172/JCI87366 CrossRefPubMedPubMedCentral

Ryan Richter J et al (2018) Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed/refractory multiple myeloma. J Clin Oncol. https://doi.org/10.1200/JCO.2018.36.5_suppl.TPS81 CrossRef

Sato T et al (2017) Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma. J Clin Oncol 35:9531–9531. https://doi.org/10.1200/JCO.2017.35.15_suppl.9531 CrossRef

Schaefer W et al (2011) Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA 108:11187–11192. https://doi.org/10.1073/pnas.1019002108 CrossRefPubMedPubMedCentral

Seimetz D, Lindhofer H, Bokemeyer C (2010) Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 36:458–467. https://doi.org/10.1016/j.ctrv.2010.03.001 CrossRefPubMed

Sen M, Wankowski DM, Garlie NK, Siebenlist RE, Van Epps D, LeFever AV, Lum LG (2001) Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu + tumors. J Hematother Stem Cell 10:247–260. https://doi.org/10.1089/15258160151134944 CrossRef

Shankar S et al (2018) A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 × CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors. J Clin Oncol 36:TPS2601–TPS2601. https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS2601 CrossRef

Shatz W et al (2013) Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. mAbs 5:872–881 https://doi.org/10.4161/mabs.26307 CrossRefPubMedPubMedCentral

Shepard HM, Phillips GL, C DT, Feldmann M (2017) Developments in therapy with monoclonal antibodies and related proteins. Clin Med 17:220–232. https://doi.org/10.7861/clinmedicine.17-3-220 CrossRef

Smith EJ et al (2015) A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep 5:17943 https://doi.org/10.1038/srep17943 CrossRefPubMedPubMedCentral

Spiess C, Zhai Q, Carter PJ (2015) Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 67:95–106. https://doi.org/10.1016/j.molimm.2015.01.003 CrossRefPubMed

Staerz UD, Kanagawa O, Bevan MJ (1985) Hybrid antibodies can target sites for attack by T-cells. Nature 314:628–631. https://doi.org/10.1038/314628a0 CrossRefPubMed

Stanglmaier M, Faltin M, Ruf P, Bodenhausen A, Schroder P, Lindhofer H (2008) Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 × anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int J Cancer 123:1181–1189. https://doi.org/10.1002/ijc.23626 CrossRefPubMed

Sun LL et al (2015) Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med 7:287ra270. https://doi.org/10.1126/scitranslmed.aaa4802 CrossRef

Tabernero J et al (2017) Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 35:3002–3002. https://doi.org/10.1200/JCO.2017.35.15_suppl.3002 CrossRef

Thakur A, Huang M, Lum LG (2018) Bispecific antibody based therapeutics strengths challenges. Blood Rev 32:339–347. https://doi.org/10.1016/j.blre.2018.02.004 CrossRefPubMed

Tolcher AW et al (2016) Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 × CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature. J Clin Oncol 34:TPS3105–TPS3105. https://doi.org/10.1200/JCO.2016.34.15_suppl.TPS3105 CrossRef

Topp MS et al (2014) Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32:4134–4140. https://doi.org/10.1200/jco.2014.56.3247 CrossRefPubMed

Topp MS et al (2015) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16:57–66. https://doi.org/10.1016/s1470-2045(14)71170-2 CrossRefPubMed

Topp MS et al (2017) Safety and preliminary antitumor activity of the anti-PD-1 monoclonal antibody REGN2810 alone or in combination with REGN1979, an anti-CD20 × anti-CD3 bispecific antibody, in patients with B-lymphoid malignancies. Blood 130:1495–1495

Van Loo PF, Doornbos R, Dolstra H, Shamsili S, Bakker L (2015) Preclinical evaluation of MCLA117, a CLEC12AxCD3 bispecific antibody efficiently targeting a novel leukemic stem cell associated antigen AML. Blood 126:325–325

Varghese B et al (2014) A novel CD20xCD3 bispecific fully human antibody induces potent anti-tumor effects against B cell lymphoma in Mice. Blood 124:4501–4501

Viardot A et al (2016) Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood 127:1410–1416. https://doi.org/10.1182/blood-2015-06-651380 CrossRefPubMedPubMedCentral

von Stackelberg A et al (2016) Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol 34:4381–4389. https://doi.org/10.1200/jco.2016.67.3301 CrossRef

Vries ED et al (2015) Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma. J Clin Oncol 33:TPS3097–TPS3097. https://doi.org/10.1200/jco.2015.33.15_suppl.tps3097 CrossRef

Wang M, Yin B, Wang HY, Wang RF (2014) Current advances in T-cell-based cancer immunotherapy. Immunotherapy Uk 6:1265–1278. https://doi.org/10.2217/imt.14.86 CrossRef

Watkins MP, Bartlett NL (2018) CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas. Expert Opin Investig Drugs 27:601–611 https://doi.org/10.1080/13543784.2018.1492549 CrossRefPubMed

Wermke M, Schmidt H, Ochsenreither S, Back J, Salhi Y, Bayever E (2016) 52TiPA phase 1 study of GBR 1302 in subjects with HER2-positive cancers. Ann Oncol. https://doi.org/10.1093/annonc/mdw525.52 CrossRef

Wermke M, Schmidt H, Nolte H, Ochsenreither S, Back J, Salhi Y, Bayever E (2017) A phase I study of the bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers. J Clin Oncol 35:TPS3091–TPS3091. https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS3091 CrossRef

Wermke M et al (2018) Preliminary biomarker and pharmacodynamic data from a phase I study of single-agent bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers. J Clin Oncol 36:69–69. https://doi.org/10.1200/JCO.2018.36.5_suppl.69 CrossRef

Yankelevich M, Kondadasula SV, Thakur A, Buck S, Cheung NK, Lum LG (2012) Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr Blood Cancer 59:1198–1205. https://doi.org/10.1002/pbc.24237 CrossRefPubMedPubMedCentral

Yu S et al (2017) Recent advances of bispecific antibodies in solid tumors. J Hematol Oncol 10:155. https://doi.org/10.1186/s13045-017-0522-z CrossRefPubMedPubMedCentral

Yuraszeck T, Kasichayanula S, Benjamin JE (2017) Translation and clinical development of bispecific T-cell engaging antibodies for cancer treatment. Clin Pharmacol Ther 101:634–645. https://doi.org/10.1002/cpt.651 CrossRefPubMedPubMedCentral

Zitron IM, Thakur A, Norkina O, Barger GR, Lum LG, Mittal S (2013) Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies. BMC Cancer 13:83. https://doi.org/10.1186/1471-2407-13-83 CrossRefPubMedPubMedCentral

Titel: T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances
verfasst von: Lin Yu
Jianhua Wang
Publikationsdatum: 23.02.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 4/2019
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-02867-6

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Retraction Note to: SOX2 oncogenes amplified and operate to activate AKT signalling in gastric cancer and predict immunotherapy responsiveness

Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteins

Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium

Expression of Syk and MAP4 proteins in ovarian cancer

NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance

Pathobiological role of cleft palate transmembrane protein 1 family proteins in oral squamous cell carcinoma

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie